News

NMOSD test therapy BAT4406F depletes B-cells, eases disability

BAT4406F, an experimental treatment in the pipeline of Bio-Thera Solutions, reduced the number of circulating immune B-cells that produce disease-causing antibodies in neuromyelitis optica spectrum disorder (NMOSD), translating into less disability for a small group of Chinese patients. That’s according to data from a Phase 1 clinical…

Biologic immunosuppressants work better than standard meds: Study

Biologic immunosuppressants are more effective than conventional immunosuppressants for people with neuromyelitis optica spectrum disorder (NMSOD) with self-reactive antibodies against the AQP4 protein. That’s according to real-world data from a Japanese study comparing biologic therapies — Soliris (eculizumab), Enspryng (satralizumab), Ultomiris (ravulizumab), Uplizna (inebilizumab), and…

Self-reactive antibodies more frequent in NMOSD than MOGAD

Self-reactive antibodies linked to other autoimmune diseases are more common in people with neuromyelitis optica spectrum disorder (NMOSD) than in those with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a related condition. In fact, the frequency of any other autoimmune disease was nearly six times higher in adults with NMOSD…

Shingles may be rare trigger for developing NMOSD: Case report

Shingles is caused by an infection of the varicella-zoster virus (VZV), but in rare cases, it may trigger neuromyelitis optica spectrum disorder (NMOSD), a new study reports. The study’s researchers said clinicians should look for possible signs of NMOSD in patients being treated for shingles, even though developing NMOSD…

Disability assessment tool specific to NMOSD is needed: Study

People with neuromyelitis optica spectrum disorder (NMOSD) who test positive for NMOSD-driving self-reactive antibodies against the AQP4 protein and Black patients are significantly more likely to have worse disability related to vision. These are the findings of a North American study that analyzed patient data with NMOSD-specific disability scales…

Early immunosuppressive therapy better in AQP4-positive NMOSD

Early use of immunosuppressive therapy — when compared with a later treatment start — was associated with fewer relapses and reduced disability among neuromyelitis optica spectrum disorder (NMOSD) patients with self-reactive antibodies against the AQP4 protein, a study from China showed. The data demonstrated a time-dependent treatment efficacy, with…

Low socioeconomic status tied to worse pediatric NMOSD outcomes

Children with neuromyelitis optica spectrum disorder (NMOSD) who live in disadvantaged socioeconomic neighborhoods are more likely to have more severe disease-related disabilities, a study in the U.S. indicates. Two years after a diagnosis, Black pediatric patients had significantly more severe disability, as assessed with the standard Expanded Disability Status…

Study finds altered gut bacteria in people with relapsing NMOSD

The composition of bacteria in the gut is altered in neuromyelitis optica spectrum disorder (NMOSD) patients experiencing disease relapses compared with healthy people in the same household, a study reports. Following treatment, however, the gut bacterial profiles of NMOSD patients in remission resembled those of healthy people. “The…

Polyautoimmunity may raise relapse risk in NMOSD: Study

People with neuromyelitis optica spectrum disorder (NMOSD) often have other co-occurring autoimmune diseases and those who do have a significantly higher risk of a relapse than people with NMOSD alone, a study in Portugal suggests. Long-term disability outcomes didn’t differ between the two groups, however, suggesting “appropriate treatment may…